edotreotide has been researched along with Disease Exacerbation in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Baum, RP; Kulkarni, HR; Zhang, J | 1 |
| Hirota, S; Kadoya, M; Koyama, H; Kurajoh, M; Miyoshi, A; Moriwaki, Y; Nakamoto, Y; Shoji, T; Terada, T; Tsukamoto, Y | 1 |
| Baio, SM; Bodei, L; Colandrea, M; Fazio, N; Galetta, D; Gilardi, L; Grana, CM; Mariniello, A; Paganelli, G; Papi, S; Tinelli, C; Valmadre, G | 1 |
| Bockisch, A; Broelsch, CE; Frilling, A; Kuehl, H; Li, J; Malago, M; Radtke, A; Sotiropoulos, GC | 1 |
| Applebaum, L; Barak, D; Eckstein, J; Fraenkel, M; Gross, DJ; Grozinsky-Glasberg, S; Müeller-Brand, J; Shimon, I; Walter, MA | 1 |
| Baete, K; Deroose, CM; Haustermans, K; Koole, M; Mortelmans, L; Mottaghy, FM; Terwinghe, C; Van Binnebeek, S; Van Cutsem, E; Vanbilloen, B; Verbruggen, A; Verslype, C | 1 |
| Bouterfa, H; Bushnell, D; Carlisle, T; Connolly, M; Karwal, M; Madsen, M; Menda, Y; O'Dorisio, T; Parker, S; Ponto, J; Ponto, L; Zehr, P | 1 |
| Buitrago, C; Herrmann, R; Maecke, H; Mueller-Brand, J; Pless, M; Waldherr, C | 1 |
| Freitag, P; Gratzl, O; Hausmann, O; Jermann, E; Mäcke, HR; Merlo, A; Müller-Brand, J; Otte, A; Reubi, JC; Steiner, P; Wasner, M | 1 |
3 trial(s) available for edotreotide and Disease Exacerbation
| Article | Year |
|---|---|
Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher(TM)) in patients with diffuse somatostatin receptor positive liver metastases.
Topics: Alanine Transaminase; Alkaline Phosphatase; Analysis of Variance; Aspartate Aminotransferases; Carcinoma, Neuroendocrine; Clinical Protocols; Disease Progression; Humans; Liver; Liver Neoplasms; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Tomography, Emission-Computed, Single-Photon; Yttrium Radioisotopes | 2003 |
Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial.
Topics: Aged; Carcinoma, Small Cell; Disease Progression; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Octreotide; Radionuclide Imaging; Radiopharmaceuticals; Yttrium Radioisotopes | 2004 |
Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas.
Topics: Adult; Astrocytoma; Binding, Competitive; Brain Edema; Brain Neoplasms; Diffusion; Disease Progression; Female; Glioblastoma; Glioma; Humans; Injections, Intralesional; Male; Middle Aged; Neoplasm Proteins; Octreotide; Oligodendroglioma; Pilot Projects; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Receptors, Somatostatin; Stereotaxic Techniques; Tissue Distribution; Ytterbium | 1999 |
6 other study(ies) available for edotreotide and Disease Exacerbation
| Article | Year |
|---|---|
Peptide Receptor Radionuclide Therapy Using 225Ac-DOTATOC Achieves Partial Remission in a Patient With Progressive Neuroendocrine Liver Metastases After Repeated β-Emitter Peptide Receptor Radionuclide Therapy.
Topics: Actinium; Aged; Beta Particles; Disease Progression; Female; Humans; Liver Neoplasms; Neuroendocrine Tumors; Octreotide; Receptors, Peptide; Treatment Outcome | 2020 |
Ectopic adrenocorticotropic hormone syndrome associated with olfactory neuroblastoma: acquirement of adrenocorticotropic hormone expression during disease course as shown by serial immunohistochemistry examinations.
Topics: Adrenocorticotropic Hormone; Blood Glucose; Disease Progression; Eosinophils; Esthesioneuroblastoma, Olfactory; Fluorodeoxyglucose F18; Humans; Hydrocortisone; Immunohistochemistry; Leukocyte Count; Male; Metyrapone; Middle Aged; Octreotide; Positron-Emission Tomography; Potassium; Syndrome | 2018 |
Long-term results of PRRT in advanced bronchopulmonary carcinoid.
Topics: Aged; Carcinoid Tumor; Carcinoma, Neuroendocrine; Cohort Studies; Creatinine; Data Collection; Disease Progression; Disease-Free Survival; Europe; Female; Follow-Up Studies; Humans; Lutetium; Male; Middle Aged; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Octreotide; Odds Ratio; Organometallic Compounds; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Retrospective Studies; Treatment Outcome | 2016 |
The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
Topics: Adult; Aged; Disease Progression; Female; Gallium Radioisotopes; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed; Whole Body Imaging | 2010 |
Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Female; Gastrinoma; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Octreotide; Radioisotopes; Receptors, Peptide; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2011 |
Altered biodistribution of somatostatin analogues after first cycle of Peptide receptor radionuclide therapy.
Topics: Adult; Disease Progression; Female; Humans; Indium Radioisotopes; Intestinal Neoplasms; Liver Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Positron-Emission Tomography; Radioisotopes; Receptors, Peptide; Somatostatin; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2011 |